Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 2 Issue 1, January 2021

Volume 2 Issue 1

One year of Nature Cancer

This month we celebrate one year of Nature Cancer with a specially curated collection of Nature Cancer articles and a new type of commissioned Clinical Outlook articles.

See Editorial and the One Year of Nature Cancer collection

Image: Ryan Carter / Alamy Stock Photo. Cover Design: Lauren Heslop.

Editorial

  • Editorial |

    This month marks one year since the launch of Nature Cancer. As we celebrate our first anniversary, we reflect on the past year and thank the cancer research community for embracing our journal.

Comment & Opinion

  • Clinical Outlook |

    Inhibition of the anti-apoptotic protein BCL-2 has emerged as a highly effective treatment for acute myeloid leukemia; approved lower-intensity venetoclax combination therapies are now being rapidly incorporated into an improved standard of care for this cancer. Here we recount an abbreviated history of venetoclax for acute myeloid leukemia, focusing on a selection of key studies along the path from development into the clinic.

    • Courtney D. DiNardo
    • Marina Y. Konopleva
  • Clinical Outlook |

    Recent preclinical and clinical research has led to exciting advances related to high-grade serous ovarian cancer, from examining its cellular origins to gaining insight into DNA-damage-repair mechanisms that may be leveraged for therapies. Furthermore, studies have demonstrated clinical benefit for inhibition of the polymerase PARP and modulation of the cell cycle, and have identified molecular features related to therapeutic response.

    • Michelle McMullen
    • Katherine Karakasis
    • Amit M. Oza
  • Comment |

    Precision oncology trials based on cancer biomarkers have the potential to improve outcomes by guiding the optimal choice of therapies for patients. For this to be truly achieved, computational methods such as virtual molecular tumor boards, dynamic precision medicine and digital twins are needed to support cohort selection and trial enrollment at scale.

    • Subha Madhavan
    • Robert A. Beckman
    • Paul Macklin

News & Views

  • News & Views |

    Immunostimulatory agents such as Toll-like receptor (TLR) agonists have shown promising antitumor efficacy but are associated with therapy-related toxicities when delivered systemically. Immune-stimulating antibody conjugates are now shown to deliver TLR agonists with potent preclinical antitumor activities.

    • Olivier Demaria
    • Eric Vivier
  • News & Views |

    Chronic pancreatitis is a risk factor for pancreatic cancer; however, the mechanisms underlying cellular susceptibility to oncogenic transformation are complex. A recent study reports a damage-associated progenitor cell state, controlled by the transcription factors KLF5 and members of the AP-1 family, that initiates tumorigenesis in mouse models of pancreatic cancer in which the proto-oncogene KRAS is altered.

    • Lindsay M. LaFave
    • Jason D. Buenrostro
  • News & Views |

    The diversity of tumor cell responses to cyclin-dependent kinase 4/6 (CDK4/6) inhibition in breast cancer is a question not yet fully addressed. A recent study defines the effects of CDK4/6 inhibition on chromatin organization and shows that remodeling of the cancer cell epigenome mediates some of the key biological effects of these targeted therapy agents.

    • Antoni Hurtado

Research

Amendments & Corrections

Search

Quick links